InMed Pharmaceuticals (INM) Current Deferred Revenue (2021 - 2023)

InMed Pharmaceuticals has reported Current Deferred Revenue for 3 years, with the latest figure at $28656.0 in Q4 2023.

• For the quarter ending Q4 2023, Current Deferred Revenue rose 77.21% year-over-year to $28656.0; the trailing twelve-month figure through Dec 2023 stood at $28656.0 (up 77.21% YoY), and the FY2023 full-year result was $16171.0, changed N/A from the prior year.
• Current Deferred Revenue for Q4 2023 stood at $28656.0, up from $16171.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $28656.0 in Q4 2023, with the low at $8390.0 in Q4 2021.
• Historically, Current Deferred Revenue has averaged $15737.3 across 3 years, with a median of $16171.0 in 2022.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue jumped 92.74% — and 2023, when it jumped 77.21%.
• InMed Pharmaceuticals' Current Deferred Revenue stood at $8390.0 in 2021, then jumped by 92.74% to $16171.0 in 2022, then jumped by 77.21% to $28656.0 in 2023.
• The last three Current Deferred Revenue figures came in at $28656.0 (Q4 2023), $16171.0 (Q2 2023), and $16171.0 (Q1 2023), per Business Quant data.